Table 1.
List of FDA-approved Immune Checkpoint Inhibitors (ICIs) targeting CTLA-4, PD-1 and PD-L1.
| Drug (Trade name) | Company | Date of approval | Indication | References |
|---|---|---|---|---|
| CTLA-4 inhibitors | ||||
| Ipilimumab (Yervoy®) | Bristol-Myers Squibb | 2011 | Melanoma | (2) |
| colorectal cancer | (3) | |||
| Renal cell carcinoma | (4) | |||
| PD-1 inhibitors | ||||
| Nivolumab (Opdivo®) | Bristol-Myers Squibb | 2014 | Melanoma | (5) |
| Hodgkin’s lymphoma | (6) | |||
| Diffuse large B-cell lymphoma | (7) | |||
| Urothelial cancer | (8) | |||
| Colorectal cancer | (3) | |||
| Hepatocellular carcinoma | (9) | |||
| Non-small cell lung cancer | (10) | |||
| Small cell lung cancer | (11) | |||
| Renal cell carcinoma | (12) | |||
| Squamous cell carcinoma | (13) | |||
| Pembrolizumab (Keytruda®) | Merck | 2014 | Melanoma | (14) |
| Cervical cancer | (15) | |||
| Hodgkin’s lymphoma | (16) | |||
| Diffuse large B-cell lymphoma | (17) | |||
| Gastric cancer | (18) | |||
| Urothelial cancer | (19) | |||
| Colorectal cancer | (20) | |||
| Hepatocellular carcinoma | (21) | |||
| Non-small cell lung cancer | (22) | |||
| Small cell lung cancer | (23) | |||
| Renal cell carcinoma | (24) | |||
| Squamous cell carcinoma | (25) | |||
| Esophageal cancer | (26) | |||
| Merkel cell carcinoma | (27) | |||
| Cemiplimab (Libtayo®) | Sanofi | 2018 | Cutaneous squamous cell carcinoma | (28) |
| PD-L1 inhibitors | ||||
| Atezolizumab (Tecentriq®) | Roche, Genentech | 2016 | Non-small cell lung cancer | (29) |
| Triple negative breast cancer | ||||
| Avelumab (Bavencio®) | Merck, Pfizer | 2017 | Merkel cell carcinoma | (30) |
| Renal cell carcinoma | (31) | |||
| Urothelial cancer | (32) | |||
| Durvalumab (Imfinzi®) | AstraZeneca | 2017 | Bladder cancer | (33) |
| Non-small cell lung cancer | (34) | |||